Ownership history in CITADEL ADVISORS LLC · 8 quarters on record
This page tracks every 13F SEC filing in which CITADEL ADVISORS LLC reported a position in INNATE PHARMA S A (IPHA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | REDUCED | 20,042 | -6,575 | -24.7% | 0.00% | $39K | $1.93 |
| 2025 Q2 | ADDED | 26,617 | +2,350 | +9.7% | 0.00% | $47K | $1.82 |
| 2025 Q1 | ADDED | 24,267 | +12,414 | +104.7% | 0.00% | $43K | $1.78 |
| 2024 Q4 | REDUCED | 11,853 | -9,414 | -44.3% | 0.00% | $22K | $1.84 |
| 2024 Q3 | REDUCED | 21,267 | -2,260 | -9.6% | 0.00% | $49K | $2.29 |
| 2024 Q2 | ADDED | 23,527 | +10,246 | +77.1% | 0.00% | $46K | $1.94 |
| 2023 Q2 | REDUCED | 13,281 | -11,969 | -47.4% | 0.00% | $42K | $3.08 |
| 2021 Q1 | INITIATED | 25,250 | — | — | 0.00% | $109K | $4.31 |
As of 2025 Q4 — sorted by position size